Thrivent Financial for Lutherans’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-133,429
| Closed | -$169K | – | 2558 |
|
|
2021
Q4 | $169K | Buy |
133,429
+781
| +0.6% | +$1.4K | ﹤0.01% | 2428 |
|
|
2021
Q3 | $289K | Buy |
132,648
+605
| +0.5% | +$1.65K | ﹤0.01% | 2342 |
|
|
2021
Q2 | $495K | Buy |
132,043
+12,173
| +10% | +$42.3K | ﹤0.01% | 2183 |
|
|
2021
Q1 | $391K | Sell |
119,870
-112,223
| -48% | -$402K | ﹤0.01% | 2313 |
|
|
2020
Q4 | $792K | Hold |
232,093
| – | – | ﹤0.01% | 1913 |
|
|
2020
Q3 | $947K | Sell |
232,093
-56,615
| -20% | -$215K | ﹤0.01% | 1590 |
|
|
2020
Q2 | $976K | Buy |
288,708
+1,408
| +0.5% | +$4.1K | ﹤0.01% | 1511 |
|
|
2020
Q1 | $670K | Buy |
287,300
+197,345
| +219% | +$540K | ﹤0.01% | 1553 |
|
|
2019
Q4 | $327K | Buy |
89,955
+285
| +0.3% | +$2.3K | ﹤0.01% | 2048 |
|
|
2019
Q3 | $744K | Buy |
89,670
+6,905
| +8% | +$55.9K | ﹤0.01% | 1608 |
|
|
2019
Q2 | $713K | Buy |
82,765
+5,139
| +7% | +$46K | ﹤0.01% | 1611 |
|
|
2019
Q1 | $830K | Buy |
77,626
+6,032
| +8% | +$64.6K | ﹤0.01% | 1506 |
|
|
2018
Q4 | $626K | Buy |
71,594
+6,228
| +10% | +$79.3K | ﹤0.01% | 1453 |
|
|
2018
Q3 | $1.1M | Buy |
65,366
+1,123
| +2% | +$24.3K | ﹤0.01% | 1213 |
|
|
2018
Q2 | $1.35M | Buy |
64,243
+5,234
| +9% | +$97K | ﹤0.01% | 1074 |
|
|
2018
Q1 | $949K | Sell |
59,009
-102
| -0.2% | -$2.02K | ﹤0.01% | 1267 |
|
|
2017
Q4 | $1.12M | Buy |
59,111
+12,631
| +27% | +$229K | ﹤0.01% | 1187 |
|
|
2017
Q3 | $654K | Buy |
46,480
+3,800
| +9% | +$34.4K | ﹤0.01% | 1411 |
|
|
2017
Q2 | $318K | Buy |
42,680
+1,890
| +5% | +$12.3K | ﹤0.01% | 1738 |
|
|
2017
Q1 | $265K | Buy |
40,790
+3,190
| +8% | +$17.8K | ﹤0.01% | 1783 |
|
|
2016
Q4 | $167K | Buy |
37,600
+1,930
| +5% | +$8.1K | ﹤0.01% | 1837 |
|
|
2016
Q3 | $167K | Buy |
35,670
+5,480
| +18% | +$32.5K | ﹤0.01% | 1843 |
|
|
2016
Q2 | $198K | Buy |
30,190
+3,730
| +14% | +$26.4K | ﹤0.01% | 1804 |
|
|
2016
Q1 | $168K | Buy |
26,460
+1,240
| +5% | +$6.36K | ﹤0.01% | 1788 |
|
|
2015
Q4 | $152K | Sell |
25,220
-168,240
| -87% | -$962K | ﹤0.01% | 1790 |
|
|
2015
Q3 | $1.16M | Buy |
193,460
+3,190
| +2% | +$22.1K | 0.01% | 931 |
|
|
2015
Q2 | $1.3M | Buy |
190,270
+2,680
| +1% | +$17K | 0.01% | 760 |
|
|
2015
Q1 | $1.14M | Buy |
187,590
+3,790
| +2% | +$25.2K | 0.01% | 799 |
|
|
2014
Q4 | $1.27M | Sell |
183,800
-11,300
| -6% | -$83.1K | 0.01% | 793 |
|
|
2014
Q3 | $1.59M | Buy |
195,100
+20,050
| +11% | +$157K | 0.01% | 730 |
|
|
2014
Q2 | $1.42M | Buy |
175,050
+155,100
| +777% | +$1.18M | 0.01% | 791 |
|
|
2014
Q1 | $156K | Buy |
19,950
+350
| +2% | +$2.96K | ﹤0.01% | 1507 |
|
|
2013
Q4 | $173K | Sell |
19,600
-165,200
| -89% | -$1.48M | ﹤0.01% | 1517 |
|
|
2013
Q3 | $1.55M | Sell |
184,800
-150,000
| -45% | -$1.21M | 0.01% | 631 |
|
|
2013
Q2 | $2.5K | Buy |
+334,800
| New | +$2.57M | 0.02% | 536 |
|
Other funds holding SPPI
AC
ACM
Thrivent Financial for Lutherans's SPPI Position: Q1 2022 in Review
Thrivent Financial for Lutherans sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q1 2022, closing a stake of 133,429 shares — an estimated $169K sold.
Thrivent Financial for Lutherans first reported a position in SPPI in Q2 2013 and held it in 35 quarters. The position peaked at $1.59M in Q3 2014. 101 funds tracked by Wall St. Rank hold SPPI as of Q1 2022.
- Thrivent Financial for Lutherans reported no remaining Spectrum Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
- Thrivent Financial for Lutherans sold 133,429 Spectrum Pharmaceuticals Inc shares in Q1 2022, an estimated $169K.
- Thrivent Financial for Lutherans first reported a position in Spectrum Pharmaceuticals Inc in Q2 2013 and held it in 35 quarters.
- Thrivent Financial for Lutherans's Spectrum Pharmaceuticals Inc position peaked at $1.59M in Q3 2014.
- 101 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q1 2022.
Based on Thrivent Financial for Lutherans's 13F filing for Q1 2022, filed 13 May 2022.